Renal Vein Thrombosis

1. Overview

Renal Vein Thrombosis (RVT) is the formation of thrombus within the main renal veins or their tributaries, leading to impaired venous drainage from the kidney. This condition represents a potentially serious thrombotic complication that can present acutely with dramatic symptoms or follow a chronic, insidious course. RVT is most strongly associated with nephrotic syndrome, particularly membranous nephropathy, where the profound hypercoagulable state creates ideal conditions for venous thrombosis. [1,2,3]

The clinical significance of RVT lies in its dual nature as both a complication of underlying renal disease and a potential cause of further renal impairment. Acute RVT can present with the classic triad of flank pain, haematuria, and acute kidney injury, while chronic RVT may remain asymptomatic until complications such as pulmonary embolism occur. The condition affects both adults and neonates, with distinct aetiological profiles and management approaches. [4,5]

Early recognition and appropriate anticoagulation remain the cornerstones of management, with outcomes dependent on the rapidity of diagnosis, extent of thrombosis, and successful treatment of the underlying cause. The advent of direct oral anticoagulants has expanded therapeutic options, though clinical trial evidence remains limited. Understanding RVT is essential for nephrologists, haematologists, and acute physicians managing patients with nephrotic syndrome and unexplained acute kidney injury. [6,7]

2. Epidemiology

Incidence and Prevalence

Demographics and Risk Factors

High-Risk Populations

The following groups warrant heightened surveillance for RVT:

1. Nephrotic Syndrome Patients:

   • Membranous nephropathy (highest risk: 20-37%) [9,10]
   • Serum albumin less than 20 g/L [12,13]
   • Proteinuria > 10 g/day
   • Known thrombophilia [14]

2. Neonatal Population:

   • Dehydration or hypovolaemia
   • Perinatal asphyxia
   • Maternal diabetes
   • Polycythaemia
   • Umbilical vein catheterisation [11]

3. Malignancy-Associated:

   • Renal cell carcinoma with venous invasion
   • Retroperitoneal tumours causing extrinsic compression [4,15]

3. Aetiology and Pathophysiology

Primary Causes

Pathophysiological Mechanisms

Virchow's Triad in RVT

The development of renal vein thrombosis exemplifies Virchow's classic triad of thrombogenesis:

1. Hypercoagulability (Predominant Mechanism)

The hypercoagulable state in nephrotic syndrome results from multiple simultaneous derangements: [2,3]

• Urinary Loss of Anticoagulant Proteins:

  • "Antithrombin III: Low molecular weight (58 kDa) allows glomerular filtration"
  • "Protein C and Protein S: Lost in proteinuric states"
  • "Plasminogen: Reduced fibrinolytic capacity"

• Increased Hepatic Synthesis of Procoagulants:

  • "Fibrinogen: Markedly elevated, increases blood viscosity"
  • "Factor V and Factor VIII: Increased synthesis"
  • von Willebrand factor: Elevated levels

• Platelet Abnormalities:

  • Increased platelet aggregability
  • Enhanced thromboxane production
  • Hyperlipidaemia-mediated platelet dysfunction [3,8]

• Haemoconcentration:

  • Intravascular volume depletion from hypoalbuminaemia
  • Diuretic use exacerbates volume contraction
  • Elevated haematocrit and plasma viscosity

Exam Detail: Molecular Mechanisms in Membranous Nephropathy:

Recent evidence suggests membranous nephropathy confers particularly high thrombotic risk through multiple mechanisms:

1. Severe Hypoalbuminaemia: Albumin less than 20 g/L correlates with exponential thrombotic risk increase [12,13]
2. Anti-PLA2R Antibodies: High anti-PLA2R titres associated with increased venous thrombosis risk (OR 2.4) [10]
3. Neutrophil Activation: Th17 immune response in membranous nephropathy promotes neutrophil-mediated thrombosis [16]
4. Endothelial Dysfunction: Complement activation and immune complex deposition may damage venous endothelium

The cumulative thrombotic risk in membranous nephropathy reaches 37% in some cohorts, with renal vein thrombosis being the most common site. [9,10]

2. Venous Stasis

• Reduced renal perfusion in severe nephrotic syndrome
• Prolonged bed rest or immobility
• Extrinsic venous compression (tumour, lymph nodes)
• Anatomical variants (retroaortic left renal vein) [4]

3. Endothelial Injury

• Trauma (blunt or penetrating)
• Tumour invasion by renal cell carcinoma
• Inflammation in severe pyelonephritis
• Vasculitis affecting renal vessels [4,15]

Consequences of Renal Vein Thrombosis

Once thrombus forms within the renal vein, a cascade of renal and systemic complications can develop:

Acute Phase (Hours to Days):

1. Venous Congestion:

   • Impaired venous drainage increases renal capsular pressure
   • Back-pressure into glomerular capillaries
   • Reduced glomerular filtration rate

2. Renal Oedema and Haemorrhage:

   • Interstitial oedema from venous hypertension
   • Peritubular capillary rupture → haematuria
   • Renal enlargement visible on imaging [4,5]

3. Acute Kidney Injury:

   • Bilateral RVT or RVT in solitary kidney → severe AKI
   • Unilateral RVT → often compensated by contralateral kidney
   • Ischaemic tubular injury from reduced perfusion

Chronic Phase (Weeks to Months):

1. Collateral Vein Development:

   • Capsular veins, gonadal veins, lumbar veins
   • Allows partial venous drainage
   • Explains why chronic RVT may be asymptomatic [4]

2. Renal Atrophy:

   • Chronic ischaemia leads to nephron loss
   • Cortical thinning on imaging
   • Progressive chronic kidney disease

3. Thrombus Extension:

   • Propagation into inferior vena cava (10-15% of cases) [4]
   • Left adrenal vein involvement (left adrenal vein drains into left renal vein)
   • Left gonadal vein thrombosis → acute left varicocele in males [4,5]

4. Pulmonary Embolism:

   • Occurs in up to 10-30% of untreated cases [4,7]
   • May be the presenting feature of chronic asymptomatic RVT
   • Justifies aggressive anticoagulation approach

4. Clinical Presentation

The clinical presentation of renal vein thrombosis exists on a spectrum from asymptomatic incidental findings to life-threatening acute presentations. Recognition of these patterns is essential for timely diagnosis.

Acute Renal Vein Thrombosis

Acute RVT presents with sudden-onset symptoms reflecting rapid venous obstruction and renal congestion:

Physical Examination Findings:

• General: Patient appears uncomfortable, distressed from pain
• Vital Signs: Tachycardia, hypertension (from renal ischaemia and pain), fever (low-grade)
• Abdominal Examination:
  • Costovertebral angle tenderness (flank percussion tenderness)
  • Palpable renal mass (enlarged, tender kidney) in severe cases or in neonates
  • Abdominal distension (ascites in neonates with IVC thrombosis)
• Cardiovascular: Signs of volume depletion if nephrotic syndrome present (postural hypotension)
• Lower Limbs: Oedema (nephrotic syndrome), DVT signs if concurrent thrombosis
• Genitourinary: Acute left varicocele in males [4,5]

Chronic Renal Vein Thrombosis

Chronic RVT develops gradually, allowing collateral veins to form. Many patients remain asymptomatic or have subtle findings:

Examination Findings in Chronic RVT:

• May be entirely normal in asymptomatic cases
• Stigmata of chronic nephrotic syndrome: peripheral oedema, ascites, pleural effusions
• Chronic varicocele (if longstanding left RVT)
• Evidence of CKD: pallor, uraemic features, hypertension
• Signs of pulmonary embolism: tachypnoea, tachycardia, hypoxia, pleural rub [4,5]

Neonatal Renal Vein Thrombosis

Neonatal RVT has a distinct presentation, often related to perinatal complications: [11]

Risk Factors in Neonates: [11]

• Maternal diabetes mellitus
• Perinatal asphyxia
• Dehydration (especially in context of congenital heart disease, gastroenteritis)
• Sepsis
• Polycythaemia (haematocrit > 65%)
• Umbilical vein catheterisation
• Cyanotic congenital heart disease
• Congenital nephrotic syndrome (rare)

Clinical Patterns by Underlying Aetiology

RVT Secondary to Nephrotic Syndrome: [2,3,8]

• Background of oedema, proteinuria, hypoalbuminaemia
• May present acutely with flank pain and haematuria superimposed on chronic nephrotic features
• Or insidious with worsening proteinuria and gradual eGFR decline
• Pulmonary embolism may be first thrombotic manifestation

RVT Secondary to Renal Cell Carcinoma: [15]

• Often older patients (> 50 years)
• Constitutional symptoms: weight loss, anorexia, fatigue
• Persistent microscopic or macroscopic haematuria
• Flank mass (tumour + thrombosed vein)
• Paraneoplastic phenomena: polycythaemia, hypercalcaemia, elevated inflammatory markers
• Imaging reveals renal mass with venous invasion (tumour thrombus extends into renal vein and may reach IVC/right atrium)

RVT Secondary to Thrombophilia: [14]

• Young patients without obvious nephrotic syndrome or malignancy
• May have personal or family history of VTE
• Recurrent thrombosis at unusual sites
• Consider antiphospholipid syndrome (recurrent miscarriages, livedo reticularis, thrombocytopenia)
• Screen for inherited thrombophilias (Factor V Leiden, Prothrombin G20210A, Protein C/S deficiency, Antithrombin deficiency)

5. Differential Diagnosis

When a patient presents with acute flank pain, haematuria, and/or acute kidney injury, the following conditions should be considered:

Clinical Approach to Differentiation:

• Infection vs RVT: High fever, rigors, positive urine culture → pyelonephritis. Nephrotic syndrome, lower fever, sterile pyuria → RVT
• Calculus vs RVT: CT KUB distinguishes easily. Calculus visible, no venous thrombus. Colicky pain pattern
• Malignancy vs RVT: Enhancing tumour thrombus vs non-enhancing bland thrombus. Renal mass present. Constitutional symptoms
• Renal infarction vs RVT: Arterial vs venous pathology. CT angiography shows arterial cut-off with infarction. Very high LDH (> 1000) suggests infarction. AF or endocarditis as source
• Acute GN vs RVT: RBC casts, dysmorphic RBCs, low complement → GN. Bland urine, nephrotic syndrome → RVT

6. Investigations

Diagnosis of renal vein thrombosis requires a combination of clinical suspicion, laboratory evaluation, and definitive imaging. The approach should be systematic and timely.

Laboratory Investigations

Exam Detail: Timing of Thrombophilia Testing:

Thrombophilia screens should ideally be performed when patient is not acutely anticoagulated or acutely thrombosed, as results can be affected:

• Protein C, Protein S, Antithrombin: Levels reduced by acute thrombosis, heparin therapy (antithrombin), warfarin (Protein C/S). Consider testing before anticoagulation or after completion (3 months post-treatment)
• Factor V Leiden, Prothrombin G20210A: Genetic tests, not affected by anticoagulation or acute thrombosis. Can be done anytime
• Antiphospholipid antibodies: Requires two positive tests at least 12 weeks apart for diagnosis [14]

Imaging Investigations

Imaging is essential for confirming the diagnosis of RVT and assessing complications.

First-Line Imaging: Renal Doppler Ultrasound

Ultrasound Findings Suggestive of RVT: [4,5]

• Direct Visualisation: Echogenic thrombus within renal vein lumen (most specific)
• Doppler Abnormalities:
  • Absent or reduced renal vein flow
  • Reversed diastolic flow (venous congestion)
  • High resistance arterial waveforms
• Indirect Signs:
  • Renal enlargement (acute RVT)
  • Loss of corticomedullary differentiation
  • Increased cortical echogenicity
  • Perinephric fluid collections

Sensitivity and Specificity: Approximately 80-90% sensitive and 90-95% specific in experienced hands, but highly operator-dependent. Useful as initial screening test, especially in neonates. [5]

Gold Standard Imaging: CT Venography or MR Venography

CT Venography (CTV):

CT Venography Findings: [4,5]

• Filling Defect: Low-density thrombus within renal vein lumen (diagnostic)
• Renal Enlargement: Acute RVT causes swollen kidney
• Delayed Nephrogram: Prolonged cortical enhancement from venous congestion
• Perinephric Stranding: Oedema extends into perinephric fat
• Collateral Veins: Enlarged capsular, gonadal, lumbar veins (chronic RVT)
• IVC Extension: Thrombus propagation into inferior vena cava (10-15%)
• Underlying Cause: Renal mass (tumour thrombus), retroperitoneal lymphadenopathy (compression)

Technical Consideration: CT should include delayed venous phase (60-90 seconds post-contrast) to optimally visualise renal veins. Arterial phase alone may miss venous thrombosis.

MR Venography (MRV):

MRV Indications:

• Pregnancy (avoid radiation)
• Severe iodinated contrast allergy
• Differentiation of tumour thrombus from bland thrombus (tumour enhances)
• Follow-up imaging without radiation exposure

MRV Findings: Similar to CT - filling defect in renal vein, renal enlargement, delayed enhancement, collateral veins.

Additional Imaging

Exam Detail: Imaging Algorithm for Suspected RVT:

Clinical Suspicion of RVT
(Flank pain, haematuria, AKI, nephrotic syndrome)
           ↓
   RENAL DOPPLER ULTRASOUND
           ↓
    ┌──────┴──────┐
POSITIVE         NEGATIVE but HIGH SUSPICION
(Thrombus        (Strong clinical features,
 visualised)      high-risk patient)
    ↓                      ↓
CONFIRM with          PROCEED to CT VENOGRAPHY
CT VENOGRAPHY         (Gold standard)
    ↓                      ↓
DEFINITIVE            Positive → DIAGNOSIS
DIAGNOSIS             Negative → Excludes RVT

Special Scenarios:

• Pregnancy: Start with Doppler US. If inconclusive, use MRV (avoid radiation)
• Severe AKI (Cr > 300 µmol/L): Risk-benefit assessment for contrast. Consider non-contrast MRI techniques or proceed with contrast if diagnosis critical
• Neonates: Doppler US often sufficient (higher sensitivity in small patients). CT rarely needed

Renal Biopsy

Renal biopsy is not required for diagnosis of RVT itself, but may be indicated to:

• Diagnose underlying nephrotic syndrome cause (e.g., membranous nephropathy, FSGS)
• Assess chronicity and reversibility of renal injury

Biopsy Findings in RVT: [4]

• Vascular congestion and dilatation
• Interstitial oedema and haemorrhage
• Tubular atrophy (chronic RVT)
• Underlying glomerular pathology (membranous GN, FSGS, etc.)

Caution: Biopsy should be performed with caution in acute RVT due to increased bleeding risk from venous congestion and anticoagulation.

7. Classification and Staging

RVT can be classified by several parameters to guide management and prognosis:

Temporal Classification

Anatomical Extent

Laterality

Aetiology-Based Classification

• Primary (Idiopathic) RVT: No clear underlying cause identified (rare in adults)
• Secondary RVT: Associated with identifiable condition:
  • Nephrotic syndrome (most common)
  • Malignancy
  • Thrombophilia
  • Trauma
  • Dehydration (neonates)

8. Management

The management of renal vein thrombosis involves acute stabilisation, definitive anticoagulation, treatment of underlying causes, and consideration of interventional therapies in selected cases.

Initial Assessment and Stabilisation

ABC Approach (if patient acutely unwell):

1. Airway and Breathing: Assess for pulmonary embolism (hypoxia, tachypnoea). Supplemental O₂ if SpO₂ less than 94%
2. Circulation: IV access. Fluid resuscitation if volume depleted (nephrotic syndrome). Avoid excessive fluids if oliguric AKI
3. Disability: Conscious level. Pain control (NSAIDs avoided in AKI - use opiates)

Immediate Investigations:

• Blood tests: FBC, U&Es, Cr, LFTs, albumin, coagulation screen
• Urinalysis: haematuria, proteinuria
• Imaging: Doppler US urgently, CT venography if high suspicion

Specialist Referral:

• Nephrology: All cases. Manage nephrotic syndrome, AKI, renal biopsy if needed
• Haematology: Anticoagulation guidance, thrombophilia screening
• Vascular/IR: If considering thrombolysis or thrombectomy
• Urology/Oncology: If renal cell carcinoma suspected [4,5,6]

Anticoagulation: Mainstay of Treatment

Anticoagulation is the cornerstone of RVT management to prevent thrombus propagation, pulmonary embolism, and promote renal vein recanalisation.

Initial Anticoagulation

First Choice: Low Molecular Weight Heparin (LMWH)

Alternative: Unfractionated Heparin (UFH)

Duration of Initial Anticoagulation: Minimum 5-7 days, overlapping with warfarin until INR therapeutic for 2 consecutive days, or transition to DOAC after 5 days LMWH.

Long-Term Anticoagulation

Warfarin:

Direct Oral Anticoagulants (DOACs):

DOAC Considerations in RVT:

• Evidence base from VTE trials (not RVT-specific). Extrapolated from DVT/PE data [6]
• Apixaban preferred if eGFR 30-60 (least renal clearance)
• Rivaroxaban convenient (fewer tablets, no LMWH lead-in beyond 21 days)
• No routine monitoring, but anti-Xa assays available if needed (e.g., bleeding, pre-procedure)
• Caution: Limited data in severe nephrotic syndrome (albumin less than 20 g/L) - may have altered pharmacokinetics. Consider measuring drug levels (anti-Xa)

Exam Detail: Anticoagulation Duration Decision-Making:

Reassess Duration: Review at 3-6 months. Assess ongoing risk factors, bleeding risk, patient preference. Involve Haematology in complex decisions.

Thrombolysis and Thrombectomy

Invasive therapies are reserved for severe, life-threatening cases where anticoagulation alone is insufficient.

Indications for Thrombolysis: [4,6]

• Acute bilateral RVT with severe AKI (anuria, rapidly rising Cr, dialysis-dependent)
• Acute RVT in solitary kidney with severe AKI
• Massive IVC thrombus with haemodynamic compromise
• Failure of anticoagulation (progressive thrombosis despite adequate therapy)

Catheter-Directed Thrombolysis (CDT): [4]

• Technique: Interventional radiology-guided catheter inserted into renal vein via femoral vein. Local infusion of thrombolytic agent (alteplase, urokinase)
• Advantages: Targeted delivery. Lower systemic dose than systemic thrombolysis. Higher efficacy
• Risks: Major bleeding (5-10%), including retroperitoneal haemorrhage. Requires specialist IR service
• Evidence: Case series and small studies show improved renal function in selected acute cases. No RCTs [4,6]

Surgical/Endovascular Thrombectomy:

• Indications: Very rarely used. Massive IVC/renal vein thrombus not responding to thrombolysis. Tumour thrombus (RCC - requires nephrectomy ± IVC thrombectomy)
• Technique: Open surgical or endovascular (mechanical thrombectomy devices)
• Evidence: Limited to case reports. High-risk procedure [4]

Contraindications to Thrombolysis: Active bleeding, recent surgery (less than 10 days), recent stroke (less than 3 months), uncontrolled hypertension (BP > 180/110), bleeding diathesis.

Treatment of Underlying Causes

Successful long-term management of RVT requires addressing the root cause.

Nephrotic Syndrome:

Malignancy (Renal Cell Carcinoma): [15]

• Definitive Treatment: Radical nephrectomy ± IVC thrombectomy if tumour thrombus extends into IVC
• Peri-operative Anticoagulation: Therapeutic anticoagulation pre-operatively. Hold peri-operatively. Resume post-operatively once haemostasis secure (typically 24-48h post-op)
• Post-operative: Continue anticoagulation for ≥3-6 months. Oncology follow-up for surveillance

Thrombophilia: [14]

• Inherited (Factor V Leiden, Prothrombin G20210A, Protein C/S deficiency): Long-term (often lifelong) anticoagulation if unprovoked VTE or recurrent VTE
• Antiphospholipid Syndrome: Lifelong anticoagulation (warfarin preferred, target INR 2-3). DOACs inferior in APS - avoid. Aspirin may be added in high-risk cases
• Genetic Counselling: Offer to patients with inherited thrombophilias, especially if considering family screening

Dehydration (Neonates): [11]

• Rehydration: Careful IV fluids (isotonic saline). Avoid excessive fluids if anuric
• Treat Sepsis: Broad-spectrum antibiotics if septic
• Supportive Care: Maintain perfusion, correct electrolytes, consider dialysis if severe AKI

Prophylactic Anticoagulation in Nephrotic Syndrome

A controversial area is whether to anticoagulate nephrotic patients prophylactically (before RVT occurs).

Rationale for Prophylaxis: [8,12,13]

• High thrombotic risk (5-62% depending on histology)
• Membranous nephropathy especially high risk (20-37%)
• Severe hypoalbuminaemia (less than 20 g/L) confers highest risk

Arguments Against Universal Prophylaxis:

• Bleeding risk of anticoagulation
• Many patients will not develop thrombosis
• Lack of RCT evidence
• Uncertain which patients benefit most

Current Practice (No Universal Consensus): [8,12,13]

If Prophylactic Anticoagulation Used: [8,13]

• LMWH (prophylactic or intermediate dose: e.g., enoxaparin 40 mg SC OD or 1 mg/kg OD) or DOAC (e.g., apixaban 2.5 mg BD, rivaroxaban 10 mg OD - off-label)
• Continue while severely nephrotic (albumin less than 20-25 g/L)
• Stop if remission achieved (albumin > 30 g/L, proteinuria less than 3 g/day)
• Monitor renal function (adjust LMWH dose if eGFR less than 30)
• Patient education regarding bleeding risks

KDIGO Recommendation: [8]

• Anticoagulation if RVT confirmed
• Consider prophylaxis in high-risk patients (severe nephrotic syndrome, membranous nephropathy), but individualise decision
• No strong recommendation for universal prophylaxis

Special Populations

Pregnancy:

• RVT in pregnancy is rare but nephrotic syndrome + pregnancy = very high thrombotic risk
• Anticoagulation: LMWH (warfarin teratogenic, DOACs not studied). Continue throughout pregnancy and 6 weeks postpartum minimum [6]
• Monitoring: Anti-Xa levels if dosing uncertain (renal function changes, weight changes)
• Delivery: Convert to UFH near term for easier peri-partum management. Resume LMWH postpartum

Elderly:

• Higher bleeding risk with anticoagulation (falls, polypharmacy)
• Risk-benefit assessment: Individualise. Consider reduced-intensity anticoagulation if frail
• DOAC dosing: Consider dose reduction criteria (apixaban 2.5 mg BD if age ≥80 + weight ≤60 kg or Cr ≥133) [6]

Severe CKD/Dialysis:

• Anticoagulation challenging: Most anticoagulants renally excreted or affected by dialysis
• Options: Warfarin (not renally excreted, but increased bleeding risk in ESKD). UFH (monitor APTT). Apixaban cautiously (least renal excretion) [6]
• Haematology input essential in CKD stage 4-5

Management Algorithm

CONFIRMED RENAL VEIN THROMBOSIS
(CT/MR Venography shows thrombus)
           ↓
ASSESS SEVERITY
    ┌───────────┴───────────┐
ACUTE SEVERE               CHRONIC / LESS SEVERE
(Bilateral, severe AKI,     (Unilateral, stable function,
 IVC extension, haemodynamic  asymptomatic or mild symptoms)
 compromise, solitary kidney)
    ↓                             ↓
CONSIDER:                     ANTICOAGULATION
- Catheter-directed           (Mainstay of treatment)
  thrombolysis                    ↓
- Thrombectomy                INITIAL: LMWH or UFH
(MDT decision: Nephrology,     (LMWH if eGFR > 30, UFH if less than 30)
 Haematology, IR)               5-7 days minimum
    ↓                             ↓
ANTICOAGULATION             LONG-TERM:
           ↓                  Warfarin (INR 2-3) OR DOAC
    ┌──────────────────────────┐
    DURATION OF ANTICOAGULATION
    ├─ Provoked (transient risk): 3-6 months
    ├─ Unprovoked: ≥6 months, consider indefinite
    ├─ Persistent nephrotic (albumin less than 25 g/L): Continue while nephrotic
    ├─ Thrombophilia: Often indefinite
    └─ Bilateral/IVC extension: ≥6-12 months, often indefinite
           ↓
TREAT UNDERLYING CAUSE
├─ Nephrotic syndrome: Immunosuppression (membranous → rituximab/cyclophosphamide)
├─ Malignancy (RCC): Nephrectomy ± IVC thrombectomy
├─ Thrombophilia: Lifelong anticoagulation (APS → warfarin only)
└─ Dehydration (neonates): Rehydration, treat sepsis
           ↓
MONITOR AND FOLLOW-UP
├─ Repeat imaging at 3-6 months (assess recanalisation)
├─ Monitor renal function (eGFR, proteinuria)
├─ Thrombophilia screen (if not done acutely)
└─ Haematology review: Duration of anticoagulation decision

9. Complications

Renal vein thrombosis can result in significant acute and chronic complications, affecting both renal and extra-renal systems.

Renal Complications

Thromboembolic Complications

Complications of Anticoagulation

Other Complications

10. Prognosis and Outcomes

The prognosis of renal vein thrombosis is highly variable, depending on acuity, extent, underlying cause, and rapidity of treatment.

Renal Function Recovery

Thrombus Resolution

• With Anticoagulation: 50-70% show complete or near-complete recanalisation on follow-up imaging (3-6 months) [4,6]
• Partial Recanalisation: 20-30%. Residual thrombus may organise and form chronic scar [4]
• No Recanalisation: 10-20%. Chronic occlusion with collateral vessels. Renal atrophy likely [4]

Recurrence Risk

Mortality

Prognostic Factors

Favourable Prognostic Factors:

• Unilateral RVT
• Acute presentation with early diagnosis (less than 7 days)
• Prompt anticoagulation
• Underlying cause treatable/reversible (e.g., membranous GN responsive to immunosuppression)
• Young age, no comorbidities
• Preserved baseline renal function (eGFR > 60) [4,5,6]

Adverse Prognostic Factors:

• Bilateral RVT or RVT in solitary kidney
• Delayed diagnosis (> 2 weeks)
• Chronic presentation with established renal atrophy
• Irreversible underlying cause (advanced malignancy, severe CKD)
• Elderly, multiple comorbidities
• Severe baseline renal impairment (eGFR less than 30)
• IVC extension with recurrent PE despite anticoagulation [4,5,7]

11. Prevention and Screening

Primary Prevention

In High-Risk Nephrotic Syndrome Patients: [8,12,13]

• Risk Stratification: Identify very high-risk patients (membranous nephropathy + albumin less than 20 g/L)
• Prophylactic Anticoagulation: Consider in selected high-risk cases (individualised decision, no universal guideline)
  • LMWH (enoxaparin 40 mg SC OD or 1 mg/kg OD) or
  • "DOAC (off-label: apixaban 2.5 mg BD or rivaroxaban 10 mg OD)"
  • Continue while severely nephrotic (albumin less than 20-25 g/L)
• Patient Education: Advise on VTE symptoms, seek help urgently if flank pain, leg swelling, dyspnoea
• Mobilisation: Avoid prolonged immobility. Encourage ambulation, leg exercises
• Hydration: Maintain adequate hydration (counter-intuitive in oedematous patients but avoid hypovolaemia)

In Neonatal High-Risk Settings: [11]

• Avoid Dehydration: Careful fluid management in sick neonates
• Limit Umbilical Catheter Duration: Remove when no longer essential
• Treat Underlying Conditions: Prompt management of sepsis, maternal diabetes, polycythaemia

In Malignancy: [15]

• Early Surgical Intervention: Prompt nephrectomy for localised RCC prevents progression of tumour thrombus
• Peri-operative Anticoagulation: LMWH prophylaxis peri-operatively

Secondary Prevention (Preventing Recurrence)

• Adequate Duration of Anticoagulation: Don't stop too early. Minimum 3-6 months, longer if ongoing risk factors [6,7]
• Treat Underlying Cause: Achieve remission of nephrotic syndrome, screen for thrombophilia, manage diabetes/hypertension [8,14]
• Lifestyle Modifications: Maintain healthy weight, avoid smoking, regular exercise
• Monitoring: Regular nephrology follow-up. Monitor albumin, proteinuria, eGFR. Repeat imaging if symptoms recur

Screening for RVT

When to Screen: [4,5,8]

• Symptomatic Patients: Any patient with flank pain + haematuria + nephrotic syndrome or AKI → image (Doppler US or CT venography)
• Asymptomatic High-Risk Patients: No consensus on routine screening. Some nephrologists perform screening Doppler US in:
  • Newly diagnosed membranous nephropathy with severe nephrotic syndrome (albumin less than 20 g/L)
  • Unexplained worsening of proteinuria or eGFR decline in nephrotic patient
  • Known thrombophilia + new-onset nephrotic syndrome

Screening Modality: Renal Doppler ultrasound (non-invasive, no contrast, can be repeated). If positive or high suspicion, confirm with CT/MR venography. [4,5]

12. Evidence and Guidelines

Key Evidence

Guidelines and Recommendations

Evidence Gaps:

• No RCTs comparing LMWH vs DOAC specifically in RVT
• No RCTs of prophylactic anticoagulation in high-risk nephrotic patients (ethical concerns)
• Limited data on optimal duration of anticoagulation in RVT
• Unclear role of routine screening in asymptomatic nephrotic patients

Current management extrapolates from general VTE evidence and observational RVT cohorts. [4,6,7,8]

13. Common Exam Questions

MRCP Part 2 Style Questions

Question 1: Which histological subtype of nephrotic syndrome carries the highest risk of renal vein thrombosis?

A. Minimal change disease B. Focal segmental glomerulosclerosis C. Membranous nephropathy D. IgA nephropathy E. Diabetic nephropathy

Answer: C. Membranous nephropathy (20-37% RVT risk) [8,9,10]

---

Question 2: A 35-year-old man with known membranous nephropathy presents with sudden-onset left flank pain and macroscopic haematuria. Serum albumin 18 g/L, creatinine 180 µmol/L (baseline 90). What is the most appropriate next investigation?

A. Urine microscopy and culture B. Renal ultrasound with Doppler C. CT KUB non-contrast D. Plain abdominal X-ray E. Renal biopsy

Answer: B. Renal ultrasound with Doppler (first-line imaging for suspected RVT, followed by CT venography if positive or high suspicion persists) [4,5]

---

Question 3: Which serum albumin level is most strongly associated with increased thrombotic risk in nephrotic syndrome?

A. less than 35 g/L B. less than 30 g/L C. less than 25 g/L D. less than 20 g/L E. less than 15 g/L

Answer: D. less than 20 g/L (strongest predictor, exponential risk increase) [12,13]

---

Question 4: What is the recommended minimum duration of anticoagulation for unprovoked renal vein thrombosis?

A. 6 weeks B. 3 months C. 6 months D. 12 months E. Lifelong

Answer: C. 6 months (standard VTE guidelines, with consideration for extended/indefinite if high recurrence risk) [6,7]

---

Question 5: A 28-year-old woman with nephrotic syndrome (albumin 22 g/L) is commenced on enoxaparin for confirmed RVT. Her eGFR is 25 ml/min. What is the most appropriate adjustment?

A. Continue standard dose enoxaparin B. Reduce enoxaparin dose and monitor anti-Xa levels C. Switch to unfractionated heparin with APTT monitoring D. Switch to warfarin immediately E. No anticoagulation due to bleeding risk

Answer: C. Switch to unfractionated heparin with APTT monitoring (LMWH accumulates when eGFR less than 30. UFH is safer with monitoring) [6]

Viva Points

Opening Statement: "Renal vein thrombosis is the formation of thrombus within the main renal veins or their tributaries, most commonly associated with nephrotic syndrome, particularly membranous nephropathy, which creates a profound hypercoagulable state. It presents acutely with the triad of flank pain, haematuria, and AKI, or chronically with asymptomatic venous occlusion and risk of pulmonary embolism." [1,2,3,4]

Key Facts to Mention:

• Epidemiology: 20-37% risk in membranous nephropathy, highest among glomerular diseases [9,10]
• Pathophysiology: Hypercoagulability from urinary loss of anticoagulants (antithrombin III, protein C/S) and increased hepatic synthesis of procoagulants (fibrinogen, Factor V/VIII) [2,3]
• Diagnosis: Gold standard is CT or MR venography showing filling defect in renal vein [4,5]
• Management: Anticoagulation mainstay (LMWH → warfarin or DOAC). Duration 3-6 months minimum, extended if ongoing nephrotic syndrome or thrombophilia [6,7]
• Complications: Pulmonary embolism in 10-30% if untreated, AKI, CKD [4,7]

Common Viva Questions:

1. "How does nephrotic syndrome cause hypercoagulability?"

   • Answer: Urinary losses of antithrombin III, protein C, protein S (low MW proteins filtered through damaged glomerulus). Increased hepatic synthesis of fibrinogen, Factor V, VIII. Platelet hyperaggregability. Haemoconcentration from hypovolaemia. [2,3]

2. "What is the classic triad of acute RVT?"

   • Answer: Flank pain, haematuria, acute kidney injury (though often incomplete) [4,5]

3. "Why is membranous nephropathy particularly high risk for RVT?"

   • Answer: Severe hypoalbuminaemia (less than 20 g/L common), high-grade proteinuria (> 10 g/day), immune-mediated endothelial dysfunction, neutrophil activation (Th17 response), anti-PLA2R antibodies associated with thrombosis risk. [9,10,16]

4. "What is the significance of acute left varicocele in an adult male?"

   • Answer: Highly suspicious for left renal vein thrombosis. Left gonadal vein drains into left renal vein; obstruction prevents drainage, causing varicocele. Requires urgent imaging (Doppler US or CT venography). [4,5]

5. "When would you consider catheter-directed thrombolysis?"

   • Answer: Acute bilateral RVT with severe AKI (anuria, dialysis-dependent), RVT in solitary kidney with severe AKI, massive IVC thrombus with haemodynamic compromise, failure of anticoagulation alone. Case-by-case MDT decision. [4,6]

6. "How long would you anticoagulate a patient with RVT secondary to nephrotic syndrome?"

   • Answer: Continue while nephrotic (albumin less than 25-30 g/L). If nephrotic syndrome remits (albumin normalises, proteinuria less than 3 g/day), can consider stopping after 6 months total treatment. If persistent nephrotic syndrome, continue indefinitely or until remission achieved. [6,7,8]

Common Mistakes

Mistakes that Fail Candidates:

1. Missing the diagnosis: Not considering RVT in a nephrotic patient with flank pain and haematuria. Always think RVT in this scenario [4,5]
2. Using wrong imaging: Ordering CT KUB (for stones) instead of CT venography (for RVT). CT KUB won't show venous thrombus adequately [5]
3. Inadequate anticoagulation duration: Stopping anticoagulation at 3 months in a patient with ongoing severe nephrotic syndrome (albumin 18 g/L). Should continue while nephrotic [6,8]
4. Using LMWH in severe renal impairment: Giving standard-dose enoxaparin when eGFR 20 ml/min. LMWH accumulates. Use UFH with APTT monitoring [6]
5. Missing IVC extension: Not assessing for IVC thrombus (causes bilateral leg oedema, higher PE risk). Always image IVC on CT venography [4]
6. Not screening for thrombophilia: In a young patient with unprovoked RVT, failing to check Factor V Leiden, Prothrombin G20210A, antiphospholipid antibodies. Essential for determining anticoagulation duration [14]
7. Confusing tumour thrombus with bland thrombus: Not recognising that renal cell carcinoma can cause tumour thrombus extending into renal vein. Tumour thrombus enhances on CT (bland thrombus doesn't). Treatment is surgical (nephrectomy), not just anticoagulation [15]

14. Patient and Layperson Explanation

What is Renal Vein Thrombosis?

Renal vein thrombosis (RVT) is a condition where a blood clot forms in one of the veins that carries blood away from your kidneys. Think of it like a blockage in a drainage pipe - blood can get into the kidney through the arteries, but it has difficulty leaving through the veins because of the clot.

What Causes It?

The most common cause in adults is a kidney condition called nephrotic syndrome. This causes your kidneys to leak large amounts of protein into the urine, which makes your blood more "sticky" and prone to clotting. Other causes include:

• Kidney cancer: The tumour can grow into the vein
• Dehydration: Especially in newborn babies
• Blood clotting disorders: Some people have conditions that make their blood clot more easily
• Trauma: Injury to the kidney area

What Are the Symptoms?

Sudden (Acute) RVT:

• Sudden, severe pain in your side or back (flank pain)
• Blood in your urine (making it pink or red)
• Reduced amount of urine
• Swelling in your legs (if the clot extends to the large vein in your abdomen)
• Feeling generally unwell

Gradual (Chronic) RVT:

• Sometimes no symptoms at all
• Gradual worsening of kidney function over months
• Swelling may worsen if you already have nephrotic syndrome
• Breathlessness (if a piece of the clot breaks off and travels to the lungs - this is called a pulmonary embolism)

How Is It Diagnosed?

Your doctor will:

1. Ask about your symptoms and examine you
2. Test your urine for blood and protein
3. Blood tests to check kidney function and blood clotting
4. Imaging scans:
   • Ultrasound: Uses sound waves to look at blood flow in the kidney veins (first test, painless)
   • CT scan: A detailed X-ray scan that shows the clot clearly (most accurate test, requires injection of contrast dye)

How Is It Treated?

1. Blood-Thinning Medication (Anticoagulants)

This is the main treatment. Blood thinners don't dissolve the clot, but they:

• Stop the clot from getting bigger
• Prevent new clots forming
• Allow your body's natural processes to break down the clot over time

Types of blood thinners:

• Injections: Heparin injections under the skin for the first few days
• Tablets: Warfarin or newer tablets (DOACs like rivaroxaban or apixaban) for 3-6 months or longer

You'll need regular blood tests if you take warfarin to make sure the dose is right.

2. Treating the Underlying Cause

• Nephrotic syndrome: Medications to suppress the immune system and reduce protein loss (steroids, immunosuppressants)
• Kidney cancer: Surgery to remove the affected kidney
• Dehydration (in babies): Careful fluid replacement

3. Rarely, Other Procedures

• Clot-busting drugs: Injected directly into the vein clot through a thin tube. Only used in very severe cases (e.g., both kidneys affected with kidney failure)
• Surgery: Very rare. Only if clot-busting drugs don't work

What Are the Risks?

If untreated:

• Pulmonary embolism: A piece of the clot can break off and travel to the lungs (life-threatening)
• Kidney damage: Permanent loss of kidney function, may need dialysis

With treatment:

• Most people recover well, especially if treated early
• Blood thinners have a small risk of bleeding (nosebleeds, easy bruising, rarely serious bleeding)

How Long Does Treatment Last?

• Minimum 3-6 months of blood thinners
• Longer (sometimes lifelong) if:
  • You have an ongoing blood clotting disorder
  • Nephrotic syndrome doesn't go away
  • The clot was in both kidneys or very extensive

Your doctor will review you regularly and decide when it's safe to stop blood thinners.

Will My Kidney Recover?

• If treated quickly (within a few days): Good chance of full recovery, especially if only one kidney affected
• If delayed (weeks to months): Some permanent kidney damage likely, but many people still have adequate kidney function
• Babies: 25-50% may have long-term kidney problems, need lifelong monitoring

Can It Be Prevented?

If you have severe nephrotic syndrome with very low blood protein levels, your doctor may recommend:

• Preventive blood-thinning injections or tablets while you have the condition
• Keeping well-hydrated
• Staying mobile (avoiding long periods of sitting/lying still)
• Treating the underlying kidney disease with medication

Key Messages

• RVT is a serious but treatable condition
• Early diagnosis and blood thinners are essential
• Most people recover if treated promptly
• Long-term monitoring of kidney function is important
• If you have nephrotic syndrome, be aware of symptoms (flank pain, blood in urine) and seek help urgently

Questions to Ask Your Doctor

1. What caused my renal vein thrombosis?
2. How long will I need blood-thinning medication?
3. What are the side effects of blood thinners, and what should I watch out for?
4. Will my kidney function recover completely?
5. Do I need to avoid any activities while on blood thinners (e.g., contact sports)?
6. How often will I need follow-up appointments and scans?
7. Are there any dietary restrictions I should follow?
8. What is my risk of this happening again?

---

15. References

Primary Sources

1. Mazhar HR, Aeddula NR. Renal Vein Thrombosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. PMID: 30725656.

2. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 1985;28(3):429-439. doi:10.1038/ki.1985.149

3. Downie ML, Gallibois C, Parekh RS, Noone DG. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health. 2017;37(4):248-258. doi:10.1080/20469047.2017.1374003

4. Asghar M, Ahmed K, Shah SS, et al. Renal vein thrombosis. Eur J Vasc Endovasc Surg. 2007;34(2):217-223. doi:10.1016/j.ejvs.2007.02.017

5. O'Dea MJ, Malek RS, Tucker RM, Fulton RE. Renal vein thrombosis. J Urol. 1976;116(4):410-414. doi:10.1016/s0022-5347(17)58838-2

6. Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019;210(11):516-524. doi:10.5694/mja2.50201

7. Palareti G, Santagata D, De Ponti C, et al. Anticoagulation and compression therapy for proximal acute deep vein thrombosis. Vasa. 2024;53(5):289-297. doi:10.1024/0301-1526/a001138

8. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513-520. doi:10.2215/CJN.10131011

9. Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93(6):479-485. PMID: 26977832.

10. Zhu H, Xu L, Liu X, et al. Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy. Ren Fail. 2022;44(1):594-600. doi:10.1080/0886022X.2022.2057861

11. Brandão LR, Simpson EA, Lau KK. Neonatal renal vein thrombosis. Semin Fetal Neonatal Med. 2011;16(6):323-328. doi:10.1016/j.siny.2011.08.004

12. Yang X, Wang Q, Bing B, et al. The role of neutrophils in venous thrombosis in primary membranous nephropathy is associated with thrombosis and relapses. Am J Nephrol. 2025;56(5):630-640. doi:10.1159/000545296

13. Casey D, Romero K, Patel R, et al. Bilateral renal vein thrombosis in membranous nephropathy: hypoalbuminemia predictive of venous thromboembolism in nephrotic syndrome. Cureus. 2022;14(10):e30032. doi:10.7759/cureus.30032

14. Torun C, Vural Keskinler M, Mesci B. Renal vein thrombosis associated with nephrotic syndrome and Factor V Leiden. Indian J Nephrol. 2023;33(6):478-479. doi:10.4103/ijn.ijn_37_23

15. Shiraishi K, Chesta F, Nishimura Y, Chong CM. Bilateral renal vein thrombosis and chylous ascites in phospholipase A2 receptor-associated membranous nephropathy: a case report. Cureus. 2024;16(6):e63434. doi:10.7759/cureus.63434

16. Cremoni M, Brglez V, Perez S, et al. Th17-immune response in patients with membranous nephropathy is associated with thrombosis and relapses. Front Immunol. 2020;11:574997. doi:10.3389/fimmu.2020.574997

17. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274.

18. Verma PR, Patil P. Nephrotic syndrome: a review. Cureus. 2024;16(2):e53923. doi:10.7759/cureus.53923

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines. This content was last updated January 2026.